BioCardia, Inc (BCDA) - Projected Future Earnings

BioCardia, Inc. (BCDA) generates revenue through the sale of CardiAMP systems for myocardial regeneration. Projected financial results demonstrate the business's fundamental potential, with the value recorded at 0.00. The unique Helix technology retains patients within trials despite temporary FDA pauses. The company minimizes risks by supplying specialized equipment and pharmaceuticals for the surgical treatment of heart failure.

BioCardia Inc (BCDA): Expected Net Profit from 08/22/2024 to 11/14/2024

Analytical breakdowns and data insights for company BioCardia Inc. (BCDA)

- share price and consensus valuation forecast:

Stock Price BioCardia, Inc.|BCDA - Price Target Chart

- market capitalization indicators:

Market Capitalization BioCardia|BCDA - Company Buyout Price

- book capitalization indicators:

Net Assets per Single Share BioCardia|BCDA - Total Stockholders' Equity|Market Capitalization to Book Value Ratio biocardia.com|BCDA - Cumulative Company Assets

- debt and liquidity data:

- net income and valuation ratios data:

BCDA - Net Profit|Future Profit BioCardia, Inc.|BCDA - Company Value to Net Income|Forward P/E Multiple BioCardia|BCDA - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization BioCardia|BCDA - Operating profit before amortization|Net earnings per share (EPS TTM) BioCardia|BCDA - Net earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months biocardia.com|BCDA - Expected net earnings per share growth this year|Earnings growth forecast for next year BioCardia, Inc.

Fundamental company valuation:BioCardia, Inc., BCDA

Projected profit assesses future cash flows, allowing analysts to avoid value traps when evaluating declining assets. This metric measures a business's fundamental resilience to external shocks by calculating expected earnings. The projected profit trend for BioCardia, Inc. (BCDA) reflects the monetization of the CardiAMP system. Inelastic demand for myocardial therapy provides the company with significant pricing power. This confirms the long-term adaptability of the model and minimizes the risk of overpayment.

Competing companies